Latest Healthcare News

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

Ramsay Health Care has cleared a major regulatory hurdle with ACCC approval to acquire National Capital Private Hospital, setting the stage for completion in early fiscal 2027.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited has announced an ordinary dividend of AUD 2.15 per share for the six months ending December 2025, with payments scheduled for April 2026 and options for currency conversion based on shareholder location.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Pro Medicus has reported its strongest half-year performance yet, with revenue and profits surging alongside a wave of new multi-million dollar contracts and strategic AI investments. The healthcare IT leader is expanding its global footprint and cloud capabilities, setting the stage for sustained growth.

BlinkLab has expanded its pivotal FDA 510(k) autism diagnostic trial to nine top U.S. sites, adding Drexel University ahead of the Q1 2026 study start. This move follows a successful pilot study that exceeded FDA benchmarks, positioning BlinkLab Dx 1 for regulatory clearance.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.

Pro Medicus Limited has reported a stellar half-year performance with revenue up 28.4% and a surge in net profit, driven by major US contract wins and strategic investments.